<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05625347</url>
  </required_header>
  <id_info>
    <org_study_id>BORA-1A-C302</org_study_id>
    <nct_id>NCT05625347</nct_id>
  </id_info>
  <brief_title>Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function</brief_title>
  <official_title>A Single-dose, Open-label, Multi-center, Randomized, 2-treatment Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vectura, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vectura, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to compare the pharmacokinetics (PK) pharmacodynamics&#xD;
      (PD), safety and tolerability of acetylsalicylic acid powder for oral inhalation (I-ASA) with&#xD;
      non-enteric-coated chewable aspirin (C-ASA) in adult subjects with obstructive or restrictive&#xD;
      pulmonary function.&#xD;
&#xD;
      In the first treatment period, subjects will be randomized to receive either a single dose&#xD;
      (100 mg) of I-ASA powder via a Dry Powder Inhaler (DPI) OR a single dose (162 mg) of C-ASA&#xD;
      tablets. After a washout period, subjects will be crossed over to receive the other treatment&#xD;
      in the second treatment period. All subjects will receive both treatments during the study.&#xD;
      Each single dose treatment will be followed by up to 24 hours of serial post-dose PK, PD, and&#xD;
      safety/tolerability assessments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 16 adult males and females subjects are planned for enrollment in this study, to&#xD;
      achieve a minimum of 10 subjects with evaluable PD/PK, safety, and tolerability data:&#xD;
&#xD;
        -  5 subjects with obstructive lung function [i.e., diagnosed with chronic obstructive&#xD;
           pulmonary disease (COPD)]; and&#xD;
&#xD;
        -  5 subjects with restrictive lung function&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2023</start_date>
  <completion_date type="Anticipated">July 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 11, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration of ASA (Cmax)</measure>
    <time_frame>pre-dose and 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the ASA plasma concentration versus time curve (AUC0-inf)</measure>
    <time_frame>pre-dose and 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the ASA plasma concentration versus time curve (AUC0-t)</measure>
    <time_frame>pre-dose and 24 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of plasma concentrations of ASA.</measure>
    <time_frame>assessed up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of plasma concentrations of SA.</measure>
    <time_frame>assessed up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of SA.</measure>
    <time_frame>minutes post-dose: 2, 5, 10, 20, 30, 45, 60, 120, 180, 240, 360, 480, 720</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC0-inf) of SA.</measure>
    <time_frame>minutes post-dose: 2, 5, 10, 20, 30, 45, 60, 120, 180, 240, 360, 480, 720</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC0-t) of SA.</measure>
    <time_frame>minutes post-dose: 2, 5, 10, 20, 30, 45, 60, 120, 180, 240, 360, 480, 720</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum thromboxane B2 (TxB2) serum concentration - Area under the effect curve (AUEC) of the % Change from baseline (CFB) in serum TxB2 concentration (TxB2 suppression).</measure>
    <time_frame>24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TxB2 serum concentration - AUEC of the % CFB in serum TxB2 concentration (TxB2 suppression).</measure>
    <time_frame>20 minutes post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TxB2 serum concentration - AUEC of the % CFB in serum TxB2 concentration (TxB2 suppression)</measure>
    <time_frame>30 minutes post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving significant inhibition of platelet aggregation (&lt;550 Aspirin Reaction Units [ARU])</measure>
    <time_frame>2 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to significant reduction in platelet aggregation (&lt;550 ARU)</measure>
    <time_frame>assessed up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to half-maximal % inhibition (suppression) of serum TxB2 (ID-50).</measure>
    <time_frame>assessed up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum % inhibition of serum TxB2.</measure>
    <time_frame>assessed up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum inhibition of platelet aggregation, assessed by VerifyNow Aspirin test.</measure>
    <time_frame>assessed up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum % CFB in ARU assessed by VerifyNow tests.</measure>
    <time_frame>assessed up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum % CFB in urinary 11-dehydro-TxB2.</measure>
    <time_frame>assessed up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum % CFB in serum 6-keto-PGF1α levels.</measure>
    <time_frame>assessed up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and frequency of adverse events</measure>
    <time_frame>Screening through the 7-day follow-up period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Obstructive Pulmonary Function</condition>
  <condition>Restrictive Pulmonary Function</condition>
  <arm_group>
    <arm_group_label>Arm 1: I-ASA 100mg, then C-ASA 162mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI.&#xD;
Treatment B: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA) tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: C-ASA 162mg tablet, then I-ASA 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA)tablets.&#xD;
Treatment B: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose (100 mg) of ASA</intervention_name>
    <description>powder for oral inhalation via a Dry Powder Inhaler (DPI)</description>
    <arm_group_label>Arm 1: I-ASA 100mg, then C-ASA 162mg tablet</arm_group_label>
    <arm_group_label>Arm 2: C-ASA 162mg tablet, then I-ASA 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose (162 mg) of non-enteric-coated chewable aspirin tablets</intervention_name>
    <description>orally administered</description>
    <arm_group_label>Arm 1: I-ASA 100mg, then C-ASA 162mg tablet</arm_group_label>
    <arm_group_label>Arm 2: C-ASA 162mg tablet, then I-ASA 100mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Cohorts&#xD;
&#xD;
          -  Subjects must meet all of the following criteria to be included in the study:&#xD;
&#xD;
          -  Male or female, ≥ 40 years of age.&#xD;
&#xD;
          -  BMI &gt;18.0 and &lt;35.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females.&#xD;
&#xD;
          -  Clinically stable as determined by medical history, physical examination, vital signs,&#xD;
             and clinical laboratory evaluation.&#xD;
&#xD;
          -  Female subjects of non-childbearing potential must be: post-menopausal; or surgically&#xD;
             sterile at least 3 months prior to first dosing.&#xD;
&#xD;
          -  Sexually active female subjects of childbearing potential must be willing to use an&#xD;
             acceptable contraceptive method throughout the study as detailed in protocol.&#xD;
&#xD;
          -  Smoker (no more than 25 cigarettes or equivalent daily) or non-smoker.&#xD;
&#xD;
        Obstructive Pulmonary Function Cohort&#xD;
&#xD;
          -  Subject with a smoking history of at least 10 pack-years.&#xD;
&#xD;
          -  Subject with an established diagnosis of COPD at least 12 months prior to the&#xD;
             screening visit AND confirmed at screening by spirometry, with a post bronchodilator&#xD;
             FEV1 greater than 40% and equal to or less than 70% of the subject's normal predicted&#xD;
             value and a post-bronchodilator FEV1 greater than 40% and equal to or less than 70% of&#xD;
             the subject's normal predicted value and a post-bronchodilator FEV1/ FVC ratio &lt; 0.70.&#xD;
&#xD;
          -  Subject on stable uninterrupted maintenance COPD therapy for at least 3 months prior&#xD;
             to screening as per SoC and without any history of moderate or severe exacerbations&#xD;
             within 6 months prior to screening.&#xD;
&#xD;
        Restrictive Pulmonary Function Cohort&#xD;
&#xD;
          -  Subject with a history and documented prior diagnosis of underlying chronic&#xD;
             respiratory or cardiac disease with restrictive pulmonary function as confirmed at the&#xD;
             screening visit by:&#xD;
&#xD;
          -  FEV1/FVC ≥ 0. 7 and&#xD;
&#xD;
          -  FVC &lt; LLN (or &lt; 80% predicted) and&#xD;
&#xD;
          -  TLC &lt; 5th percentile predicted (or &lt; 80% predicted) and&#xD;
&#xD;
          -  DLCO ≤ 75% to ≥ 35% predicted&#xD;
&#xD;
          -  Continued uninterrupted SoC therapy for underlying disease for at least 12 consecutive&#xD;
             weeks immediately prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All Cohorts:&#xD;
&#xD;
          -  Presence of clinically significant uncontrolled or unstable cardiovascular, pulmonary,&#xD;
             hepatic, renal, endocrinological, hematological, immunologic, metabolic,&#xD;
             psychological, neurological, or gastrointestinal disease.&#xD;
&#xD;
          -  Any new clinically significant abnormal finding at physical examination at screening.&#xD;
&#xD;
          -  Positive serology test results for HBsAg, HCV antibody, or HIV antigen and antibody,&#xD;
             or TB test at screening.&#xD;
&#xD;
          -  Positive pregnancy test or lactating female subject.&#xD;
&#xD;
          -  Positive urine drug screen or alcohol breath test.&#xD;
&#xD;
          -  Positive test for active COVID-19.&#xD;
&#xD;
          -  Known allergic reactions, hypersensitivity or contraindications to ASA, ibuprofen,&#xD;
             other NSAID, or other related drugs, or to any excipient in the formulation.&#xD;
&#xD;
          -  Known lack of response (lack of effect) to aspirin in the past.&#xD;
&#xD;
          -  Clinically significant ECG abnormalities or vital signs abnormalities at screening.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory parameters at screening&#xD;
&#xD;
          -  Presence of active or latent tuberculosis.&#xD;
&#xD;
          -  History of asthma, including childhood asthma, syndrome of asthma, rhinitis (including&#xD;
             allergic rhinitis), nasal polyps, angioedema, urticaria, angioedema, or bronchospasm&#xD;
             that in investigator's opinion is not suitable to participate in the study.&#xD;
&#xD;
          -  Subject with current asthma defined as post-bronchodilator FEV1 &gt; 12% increase AND&#xD;
             &gt;200 ml absolute increase from pre-bronchodilator values.&#xD;
&#xD;
          -  History of non-trauma related hemorrhage.&#xD;
&#xD;
        Restrictive Pulmonary Function Cohort&#xD;
&#xD;
          -  Subject had lung surgery, with lung removal, as the reason for restrictive pulmonary&#xD;
             function.&#xD;
&#xD;
          -  Subject receiving systemic corticosteroid treatment of prednisone &gt; 10 mg/day or&#xD;
             equivalent within 3 months of screening.&#xD;
&#xD;
          -  Subject suffers from restrictive pulmonary function, co-existent with obstructive&#xD;
             pulmonary function disease.&#xD;
&#xD;
          -  Subject has baseline resting oxygen saturation of &lt; 89% on room air.&#xD;
&#xD;
          -  Subject in need of continuous oxygen use and/or prescribed long-term continuous home&#xD;
             oxygen therapy.&#xD;
&#xD;
        Other Protocol defined I/E criteria that apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pankaj Goyal, M.D.</last_name>
    <phone>+41 (58) 242 23 58</phone>
    <email>Pankaj.Goyal@vecturafertinpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Misty D'Ottavio, RN</last_name>
    <phone>(919) 996-0332</phone>
    <email>misty.dottavio@vecturafertinpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Site Partners, LLC CSP Orlando</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Only</last_name>
      <phone>407-740-8078</phone>
      <phone_ext>239</phone_ext>
      <email>aonly@flourishresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Bliden</last_name>
      <phone>410-601-1412</phone>
      <email>kbliden@lifebridgehealth.org</email>
    </contact>
    <investigator>
      <last_name>Paul Gurbel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Salm, M.D.</last_name>
      <phone>856-753-7335</phone>
      <email>a.salm@cenexel.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 21, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>April 27, 2023</last_update_submitted>
  <last_update_submitted_qc>April 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASA</keyword>
  <keyword>acetylsalicylic acid</keyword>
  <keyword>cyclooxygenase-1 enzyme</keyword>
  <keyword>COPD</keyword>
  <keyword>oral inhalation</keyword>
  <keyword>inhaled</keyword>
  <keyword>myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

